Lorenz Risch

Prof. Dr. Lorenz Risch


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
JTJulia Telser
Julia Telser
KGKirsten Grossmann
Kirsten Grossmann
OWOrnella Céline Weideli
Ornella Céline Weideli
DHDorothea Hillmann
Dorothea Hillmann
SAStefanie Aeschbacher
Stefanie Aeschbacher
LRLorenz Risch
Lorenz Risch
It is unknown whether neurological symptoms are associated with brain injury after SARS-CoV-2 infections and whether brain injury and related symptoms also emerge in Long-COVID patients. Biomarkers such as serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) can be used to elucidate neuro-axonal and astroglial injuries. We investigated whether these biomarkers are associated with COVID-19 infection status, associated symptoms and Long-COVID. From 146 individuals of the general population with a post-acute, mild-to-moderate SARS-CoV-2 infection, sNfL and sGFAP were measured before, during and after (five and ten months) the infection. Individual symptoms and Long-COVID status were assessed using questionnaires. Neurological associated symptoms were described for individuals after a mild and moderate COVID-19 infection; however, sNfL (p = 0.74) and sGFAP (p = 0.24) did not change and were not associated with headache (p = 0.51), fatigue (p = 0.93), anosmia (p = 0.77) or ageusia (p = 0.47). In Long-COVID patients, sGFAP (p = 0.038), but not sNfL (p = 0.58), significantly increased but was not associated with neurological associated symptoms. Long-COVID status, but not post-acute SARS-CoV-2 infections, may be associated with astroglial injury/activation, even if neurological associated symptoms were not correlated.

16 February 2023 in medRxiv
Verified
Preprint
Open access
PDF file
JTJulia Telser
Julia Telser
KGKirsten Grossmann
Kirsten Grossmann
OWOrnella C Weideli
Ornella C Weideli
DHDorothea Hillmann
Dorothea Hillmann
SAStefanie Aeschbacher
Stefanie Aeschbacher
LRLorenz Risch
Lorenz Risch
Background: During and after mild (no hospitalization) or moderate (hospitalization without ICU) SARS-CoV-2 infections, a wide range of symptoms, including neurological disorders have been reported. It is, however, unknown if these neurological symptoms are associated with brain injury and whether brain injury and related symptoms also emerge in patients suffering from Long-COVID. Neuronal biomarkers such as serum neurofilament light chain and glial fibrillary acidic protein can be used to elucidate neuro-axonal and astroglial injuries. We therefore investigated whether these biomarkers are associated with the COVID-19 infection status (mild-to-moderate), the associated symptoms and Long-COVID. Methods: From 146 individuals of the general population with a post-acute, mild-to-moderate SARS-CoV-2 infection, serum neurofilament light chain (sNfL; marker of intra-axonal neuronal injury) and serum glial fibrillary acidic protein (sGFAP; marker of astrocytic activation/injury) were measured. Samples were taken before, during and after (five and ten months) a SARS-CoV-2 infection. Individual symptoms and Long-COVID status were assessed using questionnaires. Results: Neurological symptoms were described for individuals after a mild and moderate COVID-19 infection, however, serum markers of brain injury (sNfL/sGFAP) did not change after an infection (sNfL: P = 0.74; sGFAP: P = 0.24) and were not associated with headache ( P = 0.51), fatigue ( P = 0.93), anosmia ( P = 0.77) and ageusia ( P = 0.47). In participants with Long-COVID, sGFAP ( P = 0.038), but not sNfL ( P = 0.58) significantly increased but was not associated with neurological symptoms. Conclusion: Neurological symptoms in individuals after a mild-to-moderate SARS-CoV-2 infection with and without Long-COVID were not associated with brain injury, although there was some astroglial injury observed in Long-COVID patients. Funding: The COVI-GAPP study received grants from the Innovative Medicines Initiative (IMI grant agreement number 101005177), the Princely House of Liechtenstein, the government of the Principality of Liechtenstein, and the Hanela Foundation (Switzerland). None of the funders played a role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to publish.

Verified
Open access
PDF file
SNSukrit Narula
Sukrit Narula
PMPedrum Mohammadi-Shemirani
Pedrum Mohammadi-Shemirani
SAStefanie Aeschbacher
Stefanie Aeschbacher
MCMichael R. Chong
Michael R. Chong
ALAnn Le
Ann Le
DCDavid Conen
David Conen
Genetic predisposition is a risk factor for office hypertension. We sought to determine whether genetic predisposition identifies individuals with ambulatory daytime hypertension. 1444 participants from the GAPP study (ages 25–41) were analyzed. We evaluated two measures of predisposition to hypertension: family history and polygenic risk scores (PRS). We evaluated correlation of predisposition with blood pressure traits and compared incremental value of each predisposition measure to a validated ambulatory BP prediction model. 12% of participants had office hypertension, while 37% had out-of-office hypertension. The correlation between PRS and family history of hypertension was low (R2 = 4.96x10-3), but both were strongly associated with ambulatory blood pressure (2.2 mmHg per 1 SD increase [95% CI: 1.6, 2.7] & 2.4 mmHg increase with positive family history [95% CI: 1.3, 3.4], respectively). PRS provides incremental improvement predicting ambulatory systolic blood pressure beyond a validated blood pressure prediction score (ΔAIC = −33), whereas family history does not (ΔAIC = 1). The difference between a baseline prediction algorithm for identifying ambulatory systolic hypertension (positive likelihood ratio of 6.87 [95% CI: 5.56, 8.49]; negative likelihood ratio of 0.45 [95% CI: 0.39, 0.51]) and the same model with PRS integrated (positive likelihood ratio of 7.69 [95% CI: 6.18, 9.57]; negative likelihood ratio of 0.43 [95% CI: 0.37, 0.49]) was modest. In a white European sample from Liechtenstein, PRS provides incremental information in identification of individuals with ambulatory hypertension, unlike family history. However, these gains are modest and warrant further development to improve predictive utility at the point-of-care.

Verified
Open access
PDF file
SNSukrit Narula
Sukrit Narula
PMPedrum Mohammadi-Shemirani
Pedrum Mohammadi-Shemirani
SAStefanie Aeschbacher
Stefanie Aeschbacher
MCMichael R. Chong
Michael R. Chong
ALAnn Le
Ann Le
DCDavid Conen
David Conen
Genetic predisposition is a risk factor for office hypertension. We sought to determine whether genetic predisposition identifies individuals with ambulatory daytime hypertension. 1444 participants from the GAPP study (ages 25–41) were analyzed. We evaluated two measures of predisposition to hypertension: family history and polygenic risk scores (PRS). We evaluated correlation of predisposition with blood pressure traits and compared incremental value of each predisposition measure to a validated ambulatory BP prediction model. 12% of participants had office hypertension, while 37% had out-of-office hypertension. The correlation between PRS and family history of hypertension was low (R2 = 4.96x10-3), but both were strongly associated with ambulatory blood pressure (2.2 mmHg per 1 SD increase [95% CI: 1.6, 2.7] & 2.4 mmHg increase with positive family history [95% CI: 1.3, 3.4], respectively). PRS provides incremental improvement predicting ambulatory systolic blood pressure beyond a validated blood pressure prediction score (ΔAIC = −33), whereas family history does not (ΔAIC = 1). The difference between a baseline prediction algorithm for identifying ambulatory systolic hypertension (positive likelihood ratio of 6.87 [95% CI: 5.56, 8.49]; negative likelihood ratio of 0.45 [95% CI: 0.39, 0.51]) and the same model with PRS integrated (positive likelihood ratio of 7.69 [95% CI: 6.18, 9.57]; negative likelihood ratio of 0.43 [95% CI: 0.37, 0.49]) was modest. In a white European sample from Liechtenstein, PRS provides incremental information in identification of individuals with ambulatory hypertension, unlike family history. However, these gains are modest and warrant further development to improve predictive utility at the point-of-care.

Verified
Open access
PDF file
SNSukrit Narula
Sukrit Narula
PMPedrum Mohammadi-Shemirani
Pedrum Mohammadi-Shemirani
SAStefanie Aeschbacher
Stefanie Aeschbacher
MCMichael R. Chong
Michael R. Chong
ALAnn Le
Ann Le
DCDavid Conen
David Conen
Genetic predisposition is a risk factor for office hypertension. We sought to determine whether genetic predisposition identifies individuals with ambulatory daytime hypertension. 1444 participants from the GAPP study (ages 25–41) were analyzed. We evaluated two measures of predisposition to hypertension: family history and polygenic risk scores (PRS). We evaluated correlation of predisposition with blood pressure traits and compared incremental value of each predisposition measure to a validated ambulatory BP prediction model. 12% of participants had office hypertension, while 37% had out-of-office hypertension. The correlation between PRS and family history of hypertension was low (R2 = 4.96x10-3), but both were strongly associated with ambulatory blood pressure (2.2 mmHg per 1 SD increase [95% CI: 1.6, 2.7] & 2.4 mmHg increase with positive family history [95% CI: 1.3, 3.4], respectively). PRS provides incremental improvement predicting ambulatory systolic blood pressure beyond a validated blood pressure prediction score (ΔAIC = −33), whereas family history does not (ΔAIC = 1). The difference between a baseline prediction algorithm for identifying ambulatory systolic hypertension (positive likelihood ratio of 6.87 [95% CI: 5.56, 8.49]; negative likelihood ratio of 0.45 [95% CI: 0.39, 0.51]) and the same model with PRS integrated (positive likelihood ratio of 7.69 [95% CI: 6.18, 9.57]; negative likelihood ratio of 0.43 [95% CI: 0.37, 0.49]) was modest. In a white European sample from Liechtenstein, PRS provides incremental information in identification of individuals with ambulatory hypertension, unlike family history. However, these gains are modest and warrant further development to improve predictive utility at the point-of-care.

18 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
URUrsula Rudin
Ursula Rudin
KGKirsten Grossmann
Kirsten Grossmann
OWOrnella Céline Weideli
Ornella Céline Weideli
JTJulia Telser
Julia Telser
SHSelina Haselmann
Selina Haselmann
LRLorenz Risch
Lorenz Risch
Background: Obstructive sleep apnea (OSA) and smoking are associated with oxidative stress, neuronal damage and cardiovascular risk. This study investigated whether subclinical sleep apnea (SSA) - undiagnosed sleep-disordered breathing - or smoking exposure and nicotine dependence are associated with serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in young, healthy adults. Method: This cross-sectional analysis included 1,125 participants from the population-based GAPP cohort (mean age 34.4 years; 51.8% female). SSA was defined as an oxygen desaturation index (ODI; number of ≥4% oxygen desaturations per hour) and/or a respiratory event index (REI; number of apneas and hypopneas per hour) of ≥5. Smoking exposure and nicotine dependence was assessed by smoking years, pack-years, and the Fagerström Test for Nicotine Dependence (FTND). Associations with serum GFAP and NfL levels were investigated using ANCOVA models adjusted for relevant confounders. Results: SSA was present in 4.5% of participants. Current and former smoking prevalence were 20.8% and 22%, respectively. GFAP levels were higher among participants with SSA, but neither GFAP nor NfL was significantly associated with SSA. In contrast, smoking exposure and nicotine dependence were inversely associated with GFAP concentrations, with smoking years remaining significant across adjusted models, whereas NfL levels showed no significant associations with smoking measures. Conclusion: In young, healthy adults, SSA was not associated with GFAP or NfL levels, whereas smoking measures were independently associated with lower GFAP concentrations but not with NfL levels, suggesting smoking-related biological processes may affect astrocytic and axonal biomarkers differently in early adulthood.